

REMARKS

Claim Amendments

Claims 1, 3-4, 7-10 and 14 have been amended to remove the term “or an *in vivo* hydrolysable ester” inasmuch as the compounds of the claims as allowed do not include free hydroxyl or carboxyl groups on which such an ester can be formed.

Claim 9 has also been amended to remove the reference to “p”, which was inadvertently left in this process for making claim when the group $(R^1)_p$ was removed from the compound claims by the Amendment and Response filed December 17, 2007.

New compound claims 21 and 22 have been added, directed to more specific selections of R^3 , R^4 , R^5 and R^6 .

- Support for R^3 being “hydrogen, chloro or fluoro” (claim 21) is found in the present specification at page 6, line 24 and in the priority application at page 5, line 31.
- Support for R^4 being a heterocyclyl selected from “tetrahydropyranyl” (claims 21 and 22) and “tetrahydrofuranyl” (claim 21) is found in the specification at page 4, lines 4-17 and in the priority application at page 3, lines 13-26. The term “heterocyclyl” is defined at specification page 4, beginning at line 4 (priority application at page 3, beginning at line 13), as “a saturated monocyclic ring, linked via a ring carbon, which contains 3-6 carbon atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen and a ring sulphur atom may be optionally oxidised to form the S-oxide(s).” The broader term “heterocyclic group” is defined at specification page 4, beginning at line 10 (priority application at page 3, beginning at line 19) in a manner that encompasses the term “heterocyclyl” as defined above. The definition of “heterocyclyl” encompasses the two saturated oxygen-containing heterocycles tetrahydropyranyl and tetrahydrofuranyl, with “tetrahydropyranyl” being specifically named at specification page 4, line 16 (priority application page 3, line 25) and “tetrahydrofuranyl” being specifically named at specification page 4, line 7 (priority application page 3, line 16).
- Support for R^5 being “methyl” (claim 21) is found in the specification at page 7, line 7 and in the priority application at page 6, line 7.

- Support for R⁶ being “C₁₋₄alkyl” (claim 21) is found in the specification at page 2, line 21 and in the priority application at page 2, line 21.

Following entry of these amendments, claims 1, 3-4, 7-10, 14 and 21-22 remain pending in this application. Inasmuch as each amendment finds support in the specification and priority application as filed, entry of these amendments is believed to be in order and is respectfully requested.

Conclusion


Each of the above amendments narrows the claims as allowed, and finds support in both the priority application and the present specification as filed, as itemized above. Accordingly, all claims pending in this application should be (or remain) allowable. Expedited consideration and allowance of all claims, and issuance of a further Notice of Allowance, is respectfully requested.

However, should there be any questions or issues outstanding, it is respectfully requested that the Examiner telephone the undersigned at the telephone number given below in order to expedite the resolution of any such question or issue and the allowance of all claims.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit

Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: January 16, 2007
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001